A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT ID: NCT06112743
Last Updated: 2025-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
63 participants
INTERVENTIONAL
2024-01-24
2026-07-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (COVID-19)
NCT04625075
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
NCT07131631
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
NCT05164744
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)
NCT04623788
Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium
NCT03607669
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mavacamten
Mavacamten
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mavacamten
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mmHg and ≥ 50 mmHg after Valsalva or after exercise.
* Left ventricular ejection fraction (LVEF) ≥ 55% at rest.
* New York Heart Association (NYHA) functional class II or III symptoms.
Exclusion Criteria
* Documented obstructive coronary artery disease or history of myocardial infarction.
* A history of resuscitated sudden cardiac arrest or life-threatening ventricular arrhythmia within 6 months prior to screening.
* An implantable cardioverter defibrillator (ICD) or pacemaker, or another contraindication for cardiac magnetic resonance imaging (CMR).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0087
West Hollywood, California, United States
Local Institution - 0003
Atlanta, Georgia, United States
Local Institution - 0093
Boston, Massachusetts, United States
Local Institution - 0090
Cleveland, Ohio, United States
Local Institution - 0086
Pittsburgh, Pennsylvania, United States
Local Institution - 0017
Houston, Texas, United States
Local Institution - 0035
Murray, Utah, United States
Local Institution - 0076
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0075
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0079
Pilar, Buenos Aires, Argentina
Local Institution - 0077
Córdoba, Córdoba Province, Argentina
Local Institution - 0074
Rosario, Santa Fe Province, Argentina
Local Institution - 0080
Buenos Aires, , Argentina
Local Institution - 0015
Camperdown, New South Wales, Australia
Local Institution - 0085
Chermside, Queensland, Australia
Local Institution - 0005
Melbourne, Victoria, Australia
Local Institution - 0001
Montreal, Quebec, Canada
Local Institution - 0068
Québec, Quebec, Canada
Local Institution - 0058
Lucerne, Luzern (de), Switzerland
Local Institution - 0029
Lugano, Ticino (it), Switzerland
Local Institution - 0061
Geneva, , Switzerland
Local Institution - 0024
Zürich (de), , Switzerland
Local Institution - 0025
Leeds, Yorkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV027-1088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.